• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1998 ARRS President's Award. The potential of in vivo vascular tissue engineering for the treatment of vascular thrombosis: a preliminary report. American Roentgen Ray Society.

作者信息

Kuo M D, Waugh J M, Yuksel E, Weinfeld A B, Yuksel M, Dake M D

机构信息

Department of Radiology, Stanford University Hospital, CA 94305, USA.

出版信息

AJR Am J Roentgenol. 1998 Sep;171(3):553-8. doi: 10.2214/ajr.171.3.9725272.

DOI:10.2214/ajr.171.3.9725272
PMID:9725272
Abstract

OBJECTIVE

Current gene therapy and tissue engineering protocols suffer from a number of inherent limitations. In this study, we examine the feasibility of a new approach for the treatment of vascular thrombosis: in vivo tissue engineering.

MATERIALS AND METHODS

Rabbit femoral veins were transfected in situ with either a previously characterized adenoviral-construct-expressing tissue plasminogen activator or a viral (adenoviral-construct-expressing beta-galactosidase) or nonviral (buffer) control and used as cross sections (n = 3). Treated veins were then harvested and grafted into the ipsilateral common femoral artery as an interposition vein graft. A potent stimulus for thrombus formation was then introduced into the recipient artery downstream of the graft. Six days later, the rabbits were sacrificed, and the grafts and downstream arteries were harvested. Vessel segments were then examined for thrombus according to defined anatomic zones. Transfection efficiency and presence of smooth muscle cells in the vein graft were also evaluated.

RESULTS

The engineered vein graft showed a significant reduction in thrombus formation within both the graft and the downstream artery relative to nonviral (buffer) and viral (adenoviral-Rous sarcoma virus beta-galactosidase [Adv/RSV-betagal]) controls. Underlying endothelial cell transfection efficiency of 90% was observed in viral controls (Adv/RSV-betagal). A 2.4-fold increase in smooth muscle alpha-actin positive cells in the engineered vein graft was seen compared with nonviral (phosphate-buffered saline) controls. A 10-fold increase in smooth muscle alpha-actin-positive cells in the engineered vein graft relative to viral (Adv/RSV-betagal) controls was also observed.

CONCLUSION

In vivo tissue engineering is a new paradigm in molecular medicine that is a viable alternative to conventional gene therapy and tissue engineering for the treatment of vascular thrombosis.

摘要

相似文献

1
1998 ARRS President's Award. The potential of in vivo vascular tissue engineering for the treatment of vascular thrombosis: a preliminary report. American Roentgen Ray Society.
AJR Am J Roentgenol. 1998 Sep;171(3):553-8. doi: 10.2214/ajr.171.3.9725272.
2
Enhancement of neointima formation with tissue-type plasminogen activator.组织型纤溶酶原激活剂增强新生内膜形成。
J Vasc Surg. 2001 Apr;33(4):821-8. doi: 10.1067/mva.2001.112323.
3
Effect of diameter of microvascular interposition vein grafts on vessel patency and free flap survival in the rat model.大鼠模型中微血管插入静脉移植物直径对血管通畅性和游离皮瓣存活的影响。
J Otolaryngol. 1999 Jun;28(3):152-7.
4
[Experimental studies on effect of grafting injury to vein graft].[静脉移植物移植损伤影响的实验研究]
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2006 Oct;20(10):1021-5.
5
An "off the shelf" vascular allograft supports angiogenic growth in three-dimensional tissue engineering.现成的血管同种移植物支持三维组织工程中的血管生成生长。
J Vasc Surg. 2011 Feb;53(2):435-44. doi: 10.1016/j.jvs.2010.08.019. Epub 2010 Oct 27.
6
In vivo suppression of vein graft disease by nonviral, electroporation-mediated, gene transfer of tissue inhibitor of metalloproteinase-1 linked to the amino terminal fragment of urokinase (TIMP-1.ATF), a cell-surface directed matrix metalloproteinase inhibitor.电穿孔介导的非病毒组织金属蛋白酶抑制剂-1 氨基末端片段与尿激酶(TIMP-1.ATF)连接的基因转移抑制静脉移植物疾病
J Vasc Surg. 2010 Feb;51(2):429-37. doi: 10.1016/j.jvs.2009.09.026. Epub 2009 Dec 24.
7
Adenoviral-mediated expression of antisense RNA to basic fibroblast growth factor reduces tangential stress in arterialized vein grafts.腺病毒介导的碱性成纤维细胞生长因子反义RNA表达可降低动脉化静脉移植物中的切向应力。
J Vasc Surg. 2000 Apr;31(4):770-80. doi: 10.1067/mva.2000.103239.
8
Small vessel replacement by human umbilical arteries with polyelectrolyte film-treated arteries: in vivo behavior.用人脐动脉和聚电解质膜处理的动脉进行小血管置换:体内行为
J Am Coll Cardiol. 2008 Nov 4;52(19):1589-97. doi: 10.1016/j.jacc.2008.08.009.
9
Thrombosis and neointima formation in vein grafts are inhibited by locally applied aspirin through endothelial protection.局部应用阿司匹林通过内皮保护作用抑制静脉移植物中的血栓形成和新生内膜形成。
Circ Res. 2004 Jun 11;94(11):1466-73. doi: 10.1161/01.RES.0000129570.06647.00. Epub 2004 Apr 29.
10
Reduction of early vein graft thrombosis by tissue plasminogen activator gene transfer.通过组织纤溶酶原激活物基因转移减少早期静脉移植物血栓形成
Thromb Haemost. 2009 Jul;102(1):145-52. doi: 10.1160/TH08-11-0772.